Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Table 1

Characteristics of the included studies.

Authors (ref)	Time	Country	Sample size		Duration of diabetes (y)		Age (y)		Intervention		Study design
			Control	Intervention	Control	Intervention	Control	Intervention	Control	Intervention
Abdollahi et al. [19]	2019	Iran	36	35	8.11 ± 6.9	9.4 ± 7.07	50.06 ± 7.69	50.14 ± 7.38	Methylcellulose	Rev 1000 mg/d 8 weeks	Double-blind, randomized, placebo-controlled, parallel trial
Bashmakov et al. [32]	2014	Egypt	10	14	15.2 ± 6.6	15.0 ± 6.9	59.8 ± 6.6	54.0 ± 10.1	Placebo	Rev 100 mg/d 60 days	Single-blind, randomized, placebo-controlled, parallel trial
Bhatt et al. [29]	2012	India	29	28	6.68 ± 4.7	7.57 ± 4.56	57.75 ± 8.71	56.67 ± 8.91	Oral hypoglycemic	Oral hypoglycemic + rev 250 mg/d 3 months	Double-blind, randomized, parallel trial
Bhatt and Nanjan [30]	2013	India	29	28	6.68 ± 4.7	7.57 ± 4.56	57.75 ± 8.71	56.67 ± 8.91	Oral hypoglycemic	Oral hypoglycemic + rev 250 mg/d 6 months	Double-blind, randomized, parallel trial
Bo et al. [37]	2016	Italy	58	59	22.6	18.5	65.4 ± 8.8	64.9 ± 8.6	Totally inert microcellulose	Rev 40 mg/d 6 months	Double-blind, randomized, placebo-controlled, parallel trial
Bo et al. [37]	2016	Italy	58	62	22.6	18.5	65.4 ± 8.8	65.0 ± 7.6	Totally inert microcellulose	Rev 500 mg/d 6 months	Double-blind, randomized, placebo-controlled, parallel trial
Goh et al. [34]	2014	Singapore	5	5	9.6 ± 6.3	9.4 ± 5.3	56.8 ± 5.3	55.8 ± 7.3	Placebo	Rev 3000 mg/d 12 weeks	Double-blind, randomized, placebo-controlled, parallel trial
Hoseini et al. [20]	2019	Iran	28	28	NA	NA	63.3 ± 10.1	61.0 ± 8.6	Placebo	Rev 500 mg/d 4 weeks	Double-blind, randomized, placebo-controlled, parallel trial
Imamura et al. [35]	2017	Japan	25	25	NA	NA	58 ± 10.1	57.4 ± 10.6	Placebo	Rev 27.97 mg/d 12 weeks	Double-blind, randomized, placebo-controlled, parallel trial
Ying et al. [26]	2017	China	31	32	1–3 y	1–3 y	64.95 ± 1.35	64.94 ± 1.36	Basic treatment	Basic treatment + rev 1000 mg/d 8 weeks	Randomized, parallel trial
Khodabandehloo et al. [21]	2018	Iran	20	25	11.25 ± 7.41	8.64 ± 6.22	61.1 ± 5.61	54.68 ± 6.72	Placebo	Rev 800 mg/d 8 weeks	Double-blind, randomized, placebo-controlled, parallel trial
Xue et al. [27]	2011	China	32	32	6.8 ± 3.4	7.7 ± 2.8	50 ± 9.7	52 ± 10.6	Basic treatment	Basic treatment + rev 1500 mg/d 4 weeks	Randomized, parallel trial
Movahed et al. [22]	2013	Iran	31	33	5.39 ± 1.36	5.81 ± 6.18	51.81 ± 6.99	52.45 ± 6.18	Totally inert microcellulose	Rev 1000 mg/d 1.5 weeks	Double-blind, randomized, placebo-controlled, parallel trial
Sattarinezhad et al. [23]	2018	Iran	30	30	14.4 ± 6.3	16.1 ± 6.6	55.7 ± 10.8	56.8 ± 9.7	Carboxymethylcellulose + losartan	Rev 500 mg/d + losartan 90 days	Double-blind, randomized, placebo-controlled, parallel trial
Seyyedebrahimi et al. [24]	2018	Iran	23	23	NA	NA	58.72 ± 6.06	54.96 ± 6.37	Placebo	Rev 800 mg/d 8 weeks	Double-blind, randomized, placebo-controlled, parallel trial
Thazhath et al. [31]	2016	Australia	14	14	5 ± 1	5 ± 1	67.5 ± 1.6	67.5 ± 1.6	Placebo	Rev 1000 mg/d 5 weeks	Double-blind, randomized, placebo-controlled, crossover trial
Timmers et al. [33]	2016	Netherlands	17	17	6.76 ± 3.96	6.76 ± 3.96	64 ± 7.87	64 ± 7.87	Placebo	Rev 150 mg/d 30 days	Double-blind, randomized, placebo-controlled, crossover trial
Tome-Carneiro et al. [36]	2013	Spain	9	13	NA	NA	57 ± 10	63 ± 12	Maltodextrin	Rev 8.1 mg/d 6 months 16.21 mg/d 6 months	Triple-blind, randomized, placebo-controlled, parallel trial
Zhang and Liu [28]	2018	China	20	20	NA	NA	57.6 ± 5.7	57.5 ± 5.9	Basic treatment	Basic treatment + rev 500 mg/d 12 weeks	Randomized, parallel trial
Zhang and Liu [28]	2018	China	20	20	NA	NA	57.6 ± 5.7	58.3 ± 5.7	Basic treatment	Basic treatment + rev 700 mg/d 12 weeks	Randomized, parallel trial
Zhang and Liu [28]	2018	China	20	20	NA	NA	57.6 ± 5.7	58.4 ± 4.8	Basic treatment	Basic treatment + rev 1000 mg/d 12 weeks	Randomized, parallel trial
Javid et al. [25]	2017	Iran	22	21	＜5	＜5	50.9 ± 8.9	49.1 ± 7.4	Placebo	Rev 240 mg/d 4 weeks	Double-blind, randomized, placebo-controlled, parallel trial